Could the cytokines concentration be a marker of IBD activity and be useful in evaluation of IBD differentiation?
Background: In inflammatory boweldisease (IBD) the imbalance betweencytokines pro- and antinflammatory isobserved.The aim of this study was the assessmentof interleukin-10 (IL-10),interleukin-6 (IL-6) and tumor necrosisfactor-α (TNF-α) concentration usefulnessin the evaluation of the activityof ulcerative colitis (UC) and Cohn’sdisease (CD).
Methods: 35 patients diagnosedwith UC and 39 with CD were examined.The control group (CG) consistedof 35 healthy volunteers. Diagnosis ofthe disease was confirmed by videocolonoscopyand histopathologicalevaluation of intestinal biopsies.Disease activity of UC was assessedaccording to the Mayo Scoring Systemand by the Crohn Disease Activiti Index(CDAI) in CD patients. Among patientswith UC 18 (51%) had severe, 14 (40%)moderate and 3 (9%) mild disease.Among patients with CD 7 (18%) wasdiagnosed with high, 27 (69%) moderate,and 5 (13%) with low activity ofthe disease. WBC, PLT, serum concentrationof TNF-α, IL-6 i IL-10 weredetermined.
Results: The average concentrationof TNF-α in UC patients was: 14.3(IQR=12.6), in CD: 12.6 (IQR=11.9), inthe CG: 3.1 (IQR=1.7). The averageconcentration of IL-6 in UC was: 19.6(IQR=21), in CD: 10.8 (IQR=7.6), in CG: 3.2 (IQR=1.6). The average concentrationof IL-10 in UC was: 14.4 (IQR=5.9),in CD: 10.4 (IQR=9.3), in the CG: 3.3(IQR=2.5). In the IBD TNF-α, IL-6 andIL-10 concentration was significantlyhigher than in CG. However, IL-10 wassignificantly higher in UC than CD. Inpatients with UC statistically significantpositive correlation between theconcentration of TNF-α, IL-6 and IL-10and disease activity was noticed. Therewere no correlation between TNF-α,IL-6 and IL-10 concentration and CDactivity.
Conclusion: Determination ofTNF-α, IL-6 and IL-10 serum concentrationcan be used for noninvasiveevaluation of inflammation activity inpatients with IBD. IL-10 concentrationmay be helpful in differentiation of UC and CD.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:73 |
|---|---|
| Enthalten in: |
Przeglad lekarski - 73(2016), 5 vom: 25., Seite 301-4 |
| Sprache: |
Polnisch |
|---|
| Beteiligte Personen: |
Cieċko-Michalska, Irena [VerfasserIn] |
|---|
| Themen: |
130068-27-8 |
|---|
| Anmerkungen: |
Date Completed 16.05.2018 Date Revised 16.05.2018 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM282787682 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM282787682 | ||
| 003 | DE-627 | ||
| 005 | 20231225034725.0 | ||
| 007 | tu | ||
| 008 | 231225s2016 xx ||||| 00| ||pol c | ||
| 028 | 5 | 2 | |a pubmed24n0942.xml |
| 035 | |a (DE-627)NLM282787682 | ||
| 035 | |a (NLM)29629745 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a pol | ||
| 100 | 1 | |a Cieċko-Michalska, Irena |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Could the cytokines concentration be a marker of IBD activity and be useful in evaluation of IBD differentiation? |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 16.05.2018 | ||
| 500 | |a Date Revised 16.05.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Background: In inflammatory boweldisease (IBD) the imbalance betweencytokines pro- and antinflammatory isobserved.The aim of this study was the assessmentof interleukin-10 (IL-10),interleukin-6 (IL-6) and tumor necrosisfactor-α (TNF-α) concentration usefulnessin the evaluation of the activityof ulcerative colitis (UC) and Cohn’sdisease (CD) | ||
| 520 | |a Methods: 35 patients diagnosedwith UC and 39 with CD were examined.The control group (CG) consistedof 35 healthy volunteers. Diagnosis ofthe disease was confirmed by videocolonoscopyand histopathologicalevaluation of intestinal biopsies.Disease activity of UC was assessedaccording to the Mayo Scoring Systemand by the Crohn Disease Activiti Index(CDAI) in CD patients. Among patientswith UC 18 (51%) had severe, 14 (40%)moderate and 3 (9%) mild disease.Among patients with CD 7 (18%) wasdiagnosed with high, 27 (69%) moderate,and 5 (13%) with low activity ofthe disease. WBC, PLT, serum concentrationof TNF-α, IL-6 i IL-10 weredetermined | ||
| 520 | |a Results: The average concentrationof TNF-α in UC patients was: 14.3(IQR=12.6), in CD: 12.6 (IQR=11.9), inthe CG: 3.1 (IQR=1.7). The averageconcentration of IL-6 in UC was: 19.6(IQR=21), in CD: 10.8 (IQR=7.6), in CG: 3.2 (IQR=1.6). The average concentrationof IL-10 in UC was: 14.4 (IQR=5.9),in CD: 10.4 (IQR=9.3), in the CG: 3.3(IQR=2.5). In the IBD TNF-α, IL-6 andIL-10 concentration was significantlyhigher than in CG. However, IL-10 wassignificantly higher in UC than CD. Inpatients with UC statistically significantpositive correlation between theconcentration of TNF-α, IL-6 and IL-10and disease activity was noticed. Therewere no correlation between TNF-α,IL-6 and IL-10 concentration and CDactivity | ||
| 520 | |a Conclusion: Determination ofTNF-α, IL-6 and IL-10 serum concentrationcan be used for noninvasiveevaluation of inflammation activity inpatients with IBD. IL-10 concentrationmay be helpful in differentiation of UC and CD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 650 | 7 | |a IL10 protein, human |2 NLM | |
| 650 | 7 | |a IL6 protein, human |2 NLM | |
| 650 | 7 | |a Interleukin-6 |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
| 650 | 7 | |a Interleukin-10 |2 NLM | |
| 650 | 7 | |a 130068-27-8 |2 NLM | |
| 700 | 1 | |a Wierzbicka-Tutka, Iga |e verfasserin |4 aut | |
| 700 | 1 | |a Szczepanek, Malgorzata |e verfasserin |4 aut | |
| 700 | 1 | |a Fedak, Danuta |e verfasserin |4 aut | |
| 700 | 1 | |a Mach, Tomasz |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Przeglad lekarski |d 1951 |g 73(2016), 5 vom: 25., Seite 301-4 |w (DE-627)NLM000063886 |x 0033-2240 |7 nnns |
| 773 | 1 | 8 | |g volume:73 |g year:2016 |g number:5 |g day:25 |g pages:301-4 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 73 |j 2016 |e 5 |b 25 |h 301-4 | ||